PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22214449-5 2012 ACE is primarily known for its ability to cleave angiotensin-I to the vasoactive octapeptide angiotensin-II, but is also able to cleave a number of other substrates including the vasodilator bradykinin and N-acetyl-seryl-aspartyl-lysyl-proline (acetyl-SDKP), a physiological modulator of hematopoiesis. goralatide 245-256 angiotensin I converting enzyme Homo sapiens 0-3 31940798-2 2020 At the same time, ACE hydrolyzes other substrates such as the vasodilator peptide bradykinin and the anti-inflammatory peptide N-acetyl-SDKP. goralatide 127-140 angiotensin I converting enzyme Homo sapiens 18-21 29411767-4 2017 In addition, the plasma level of the tetrapeptide N-acetyl-Ser-Asp-Lys-Pro was used as a marker for ACE inhibition. goralatide 50-74 angiotensin I converting enzyme Homo sapiens 100-103 26656271-0 2015 The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis. goralatide 112-119 angiotensin I converting enzyme Homo sapiens 57-60 23351021-0 2013 Antifibrotic peptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP): opportunities for angiotensin-converting enzyme inhibitor design. goralatide 21-45 angiotensin I converting enzyme Homo sapiens 75-104 23351021-2 2013 Angiotensin-converting enzyme (ACE), a key protease in the RAS, has a range of substrates, including N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP). goralatide 101-125 angiotensin I converting enzyme Homo sapiens 0-29 23351021-2 2013 Angiotensin-converting enzyme (ACE), a key protease in the RAS, has a range of substrates, including N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP). goralatide 101-125 angiotensin I converting enzyme Homo sapiens 31-34 31889494-1 2020 The two-domain dipeptidylcarboxypeptidase Angiotensin-I-converting enzyme (EC 3.4.15.1; ACE) plays an important physiological role in blood pressure regulation via the renin-angiotensin and kallikrein-kinin systems by converting angiotensin I to the potent vasoconstrictor angiotensin II, and by cleaving a number of other substrates including the vasodilator bradykinin and the anti-inflammatory peptide N-acetyl-SDKP. goralatide 405-418 angiotensin I converting enzyme Homo sapiens 88-91 26403559-2 2015 More recently, the tetrapetide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP) has emerged as a potent antifibrotic agent and negative regulator of haematopoietic stem cell differentiation which is processed exclusively by ACE. goralatide 31-55 angiotensin I converting enzyme Homo sapiens 210-213 12093364-2 2002 Mammalian ACE is responsible for the synthesis of angiotensin II and the inactivation of bradykinin and N -acetyl-Ser-Asp-Lys-Pro, but the absence of similar peptide hormones in insects suggests novel functions for Ance. goralatide 104-129 angiotensin I converting enzyme Homo sapiens 10-13 23056909-3 2012 ACE is primarily known for its ability to cleave angiotensin I (Ang I) to the vasoactive octapeptide angiotensin II (Ang II), but is also able to cleave a number of other substrates including the vasodilator bradykinin and N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP), a physiological modulator of hematopoiesis. goralatide 223-247 angiotensin I converting enzyme Homo sapiens 0-3 23056909-3 2012 ACE is primarily known for its ability to cleave angiotensin I (Ang I) to the vasoactive octapeptide angiotensin II (Ang II), but is also able to cleave a number of other substrates including the vasodilator bradykinin and N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP), a physiological modulator of hematopoiesis. goralatide 249-256 angiotensin I converting enzyme Homo sapiens 0-3 17868792-7 2007 Although similar intensity of RAS blockade can be achieved by either combination therapy or by using high doses of an AT1-receptor antagonist given alone, the ACE inhibitor present in the combination interferes with the bradykinin-nitric oxide pathway and the N-acetyl-Ser-Asp-Lys-Pro metabolism, which both may have additional biological effects. goralatide 260-284 angiotensin I converting enzyme Homo sapiens 159-162 16732017-0 2006 Assessment of patients" and physicians" compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study. goralatide 98-122 angiotensin I converting enzyme Homo sapiens 57-60 16413241-4 2006 The in vivo inhibition of ACE and NEP was monitored by measuring the urinary excretion of N-acetyl-Ser-Asp-Lys-Pro (AcSDKP) and atrial natriuretic peptide (ANP), respectively. goralatide 90-114 angiotensin I converting enzyme Homo sapiens 26-29 11167134-4 2001 Both enzymes have a K(i) of the order of 10(-7) M for the specific inhibitors studied, and are able to hydrolyze luteinizing hormone-releasing hormone and N-acetyl-Ser-Asp-Lys-Pro as described for N-domain ACE. goralatide 155-179 angiotensin I converting enzyme Homo sapiens 206-209 10805521-1 2000 N-Acetyl-Ser-Asp-Lys-Pro-OH (AcSDKP-OH), a negative regulator of hematopoietic stem cell proliferation, is shown to be a physiological substrate of angiotensin I-converting enzyme (ACE), a zinc-dipeptidyl carboxypeptidase, involved in cardiovascular homeostasis. goralatide 0-27 angiotensin I converting enzyme Homo sapiens 148-179 10856278-8 2000 The peptides angiotensin-(1-7) and N-acetyl-Ser-Asp-Lys-Pro, described as specific for N-domain ACE, were hydrolyzed by P2 and TP2, which suggests that both enzymes are N-domain ACE. goralatide 35-59 angiotensin I converting enzyme Homo sapiens 96-99 10856278-8 2000 The peptides angiotensin-(1-7) and N-acetyl-Ser-Asp-Lys-Pro, described as specific for N-domain ACE, were hydrolyzed by P2 and TP2, which suggests that both enzymes are N-domain ACE. goralatide 35-59 angiotensin I converting enzyme Homo sapiens 178-181 10805521-1 2000 N-Acetyl-Ser-Asp-Lys-Pro-OH (AcSDKP-OH), a negative regulator of hematopoietic stem cell proliferation, is shown to be a physiological substrate of angiotensin I-converting enzyme (ACE), a zinc-dipeptidyl carboxypeptidase, involved in cardiovascular homeostasis. goralatide 0-27 angiotensin I converting enzyme Homo sapiens 181-184 7876104-0 1995 The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. goralatide 27-51 angiotensin I converting enzyme Homo sapiens 127-156 34508023-0 2022 Urine N-acetyl-Ser-Asp-Lys-Pro measurement as a versatile biomarker to assess adherence to angiotensin-converting enzyme inhibitors. goralatide 6-30 angiotensin I converting enzyme Homo sapiens 91-120 34347311-1 2021 N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a physiological antifibrotic peptide that is hydrolysed by angiotensin I-converting enzyme (ACE). goralatide 39-46 angiotensin I converting enzyme Homo sapiens 110-141 34347311-1 2021 N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a physiological antifibrotic peptide that is hydrolysed by angiotensin I-converting enzyme (ACE). goralatide 39-46 angiotensin I converting enzyme Homo sapiens 143-146 34347311-5 2021 Ac-SDKP-derived analogues that are resistant to ACE degradation may provide a new avenue for fibrosis therapy. goralatide 0-7 angiotensin I converting enzyme Homo sapiens 48-51